Oppenheimer Raises Prestige Consumer Healthcare (NYSE:PBH) Price Target to $93.00

Prestige Consumer Healthcare (NYSE:PBH) had its price objective upped by analysts at Oppenheimer from $87.00 to $93.00 in a report released on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 8.62% from the stock’s current price.

A number of other equities analysts also recently issued reports on PBH. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Finally, Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.60.

Prestige Consumer Healthcare Stock Down 0.1 %

Shares of Prestige Consumer Healthcare stock opened at $85.62 on Thursday. The company has a market cap of $4.24 billion, a P/E ratio of 20.05, a PEG ratio of 2.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.10 and a current ratio of 3.68. Prestige Consumer Healthcare has a one year low of $62.35 and a one year high of $88.36. The firm has a fifty day moving average of $79.27 and a two-hundred day moving average of $75.87.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Prestige Consumer Healthcare by 3.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after purchasing an additional 49,331 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after purchasing an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth about $84,932,000. Invesco Ltd. boosted its stake in shares of Prestige Consumer Healthcare by 2.4% during the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after purchasing an additional 24,392 shares during the last quarter. Finally, Congress Asset Management Co. boosted its stake in shares of Prestige Consumer Healthcare by 5.0% during the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock worth $70,964,000 after purchasing an additional 43,619 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.